What to Know About the Prostate Cancer TURP...
Prostate cancer TURP procedure. You may be familiar with the TURP (transurethral resection of the prostate) procedure commonly used to treat benign prostatic hyperplasia (BPH), but did you know that it can also be used in men with prostate cancer. (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news
Definition of Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) - Definition of Benign Prostatic Hyperplasia (BPH) (Source: About.com Prostate Cancer)
Source: About.com Prostate Cancer - June 5, 2013 Category: Cancer & Oncology Tags: health Source Type: news
Phelps Memorial Hospital Center Urologists Are Now Using Breakthrough Laser Surgery To Treat Prostate Problems
A new laser treatment for Benign Prostate Hyperplasia (BPH) called Green Light XPS is being performed at Phelps Memorial Hospital Center in Sleepy Hollow, New York (Source: Medical Design Online News)
Source: Medical Design Online News - May 14, 2013 Category: Medical Equipment Source Type: news
Embolization Promising for Enlarged Prostate (CME/CE)
NEW ORLEANS (MedPage Today) -- Prostatic artery embolization could provide a new treatment option for men with benign prostatic hyperplasia, early results from the first prospective U.S. trial suggested. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 17, 2013 Category: Consumer Health News Source Type: news
Men With Enlarged Prostate Get Symptom Relief From Minimally-Invasive Shrinking Treatment
Enlarged prostate, or benign prostatic hyperplasia (BPH), affects most men after middle age, causing frequent nighttime trips to the bathroom and health problems. Now early findings from a small US study presented at a conference this week suggests a minimally-invasive treatment called prostatic artery embolization (PAE), which shrinks the prostate back to its more youthful size by reducing blood flow to it, may provide significant relief from symptoms and help men avoid surgery... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 16, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Holmium laser enucleation of the prostate effective in all ages
Holmium laser enucleation of the prostate seems to be a well tolerated and effective treatment option for individuals with benign prostatic hyperplasia, regardless of what age they are, report researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - April 1, 2013 Category: Urology & Nephrology Source Type: news
Active surveillance an option for some low-risk prostate cancer patients
Active surveillance of individuals with very-low-risk prostate cancer who are also on 5 α-reductase inhibitor therapy for benign prostatic hyperplasia seems to be a viable therapeutic option, say researchers. (Source: MedWire News - Urology)
Source: MedWire News - Urology - April 1, 2013 Category: Urology & Nephrology Source Type: news
Identifying Benign Prostatic Hyperplasia Patients With Increased Risk Of Prostate Cancer
Patients with benign prostatic hyperplasia (BPH) carrying prostate cancer (PCa) a risk alleles are a potential target population for PCa screening and follow-up, according to a study, which was presented at the 28th Annual EAU Congress in Milan. The study aimed to evaluate the genetic predisposition of patients with BPH to developing prostate cancer, with findings suggesting that genetic testing may offer a new tool to identify BPH patients with increased risk to develop PrCa... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 21, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news
Genetic testing may be used to identify BPH patients with increased risk of prostate cancer
(European Association of Urology) Patients with benign prostatic hyperplasia carrying prostate cancer (PCa) a risk alleles are a potential target population for PCa screening and follow-up, according to a study, which was presented yesterday at the 28th Annual EAU Congress in Milan. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 19, 2013 Category: Global & Universal Source Type: news
Urologix Names Greg Fluet as New CEO
MINNEAPOLIS, Jan. 30, 2013 -- (Healthcare Sales & Marketing Network) -- Urologix(R), Inc. (ULGX), the leading provider of in-office BPH therapy, announced today that its Board of Directors has appointed Greg Fluet as the company's Chief Executive Officer, ... Devices, Urology, PersonnelUrologix, Benign Prostatic Hyperplasia, Greg Fluet (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2013 Category: Pharmaceuticals Source Type: news
Nymox reports positive results from Phase III benign prostatic hyperplasia study of NX-1207
Nymox Pharmaceutical has reported new positive safety and efficacy data from its Phase III repeat injection study, NX02-0020, of NX-1207 for benign prostatic hyperplasia (BPH). (Source: Drug Development Technology)
Source: Drug Development Technology - January 24, 2013 Category: Pharmaceuticals Source Type: news
Nymox Announces New Positive Results in Phase 3 Repeat Injection Study of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce new positive Phase 3 safety and efficacy data for the Company's U.S. study NX02-0020. The NX02-0020 study is a prospective clinical safety evaluation of re-injection of the Company's NX-1207 drug for prostate enlargement (benign prostatic hyperplasia or BPH). Study participants consisted of 192 consecutively treated men who had previously participated in the completed NX02-0014 and NX02-0016 Phase 2 trials or in the ongoing NX02-0017 and NX02-0018 trials and who wished an open label injection of ...
Source: Medical News (via PRIMEZONE) - January 22, 2013 Category: Pharmaceuticals Source Type: news
